The ALK inhibitors market is projected to expand in the near future. This growth is driven by the rising number of cancer diagnoses, heightened awareness of ALK inhibitors, and the increasing number of these inhibitors undergoing clinical trials and seeking approval from various companies. LAS VEGAS , Aug.
30, 2024 /PRNewswire/ -- DelveInsight's ALK Inhibitors Market Insights report includes a comprehensive understanding of current treatment practices, emerging ALK inhibitors, market share of individual therapies, and current and forecasted ALK inhibitors market size from 2020 to 2034, segmented into 7MM [ the United States , the EU4 ( Germany , France , Italy , and Spain ), the United Kingdom , and Japan ]. Key Takeaways from the ALK Inhibitors Market Report At present, ALECENSA (alectinib) and ALUNBRIG (brigatinib) are the preferred first-line Anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs). ALECENSA is widely used compared to ALUNBRIG and dominates the ALK-positive NSCLC market.
Prior to the entry of ALECENSA and ALUNBRIG, XALKORI (crizotinib) was the first-line treatment choice in ALK-positive NSCLC. ALECENSA is the best-selling ALK inhibitor, with global sales of USD 1.65 billion in 2023.
Leading companies in the ALK inhibitor space are Pfizer , Takeda, Nuvalent , Hoffmann-La Roche , Xcovery Holdings , and others. Some of the key ALK inhibitors in the pipeline include Ensartinib , NVL-655 , and others. In June 2024 , a small study of ALK-positive anapl.